Recombinant Mouse VE-cadherin/CD144 protein (His Tag)
Species
Mouse
Purity
>90 %, SDS-PAGE
Tag
His Tag
Activity
not tested
Cat no : Eg0921
Validation Data Gallery
Product Information
Purity | >90 %, SDS-PAGE |
Endotoxin | <0.1 EU/μg protein, LAL method |
Activity |
Not tested |
Expression | HEK293-derived Mouse VE-cadherin protein Asp46-Ala592 (Accession# P55284) with a His tag at the C-terminus. |
GeneID | 12562 |
Accession | P55284 |
PredictedSize | 63.1 kDa |
SDS-PAGE | 65-80 kDa, reducing (R) conditions |
Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Cadherins are a family of transmembrane glycoproteins that mediate calcium-dependent cell-cell adhesion and play an important role in the maintenance of normal tissue architecture. Vascular endothelial cadherin (VE-cadherin), also known as Cadherin-5 (CDH5) or CD144, is a member of the type II classical cadherin family of cell adhesion proteins. VE-cadherin is expressed specifically in endothelial cells and mediates homophilic adhesion in the vascular endothelium. VE-cadherin plays a role in the organization of lateral endothelial junctions and in the control of permeability properties of vascular endothelium. VE-cadherin has also been shown to be required for angiogenesis.
References:
1. Julia Brasch, et al. (2011) J Mol Biol. 408(1):57-73. 2. M G Lampugnani, et al. (1992) J Cell Biol. 118(6):1511-22. 3. G Breier, et al. (1996) Blood. 87(2):630-41. 4. Yann Wallez, et al. (2006) Trends Cardiovasc Med. 16(2):55-9. 5. Dietmar Vestweber, et al. (2008) Arterioscler Thromb Vasc Biol. 28(2):223-32.